Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Trimedyne, Inc. (OTC: TMED).

Full DD Report for TMED

You must become a subscriber to view this report.


Recent News from (OTC: TMED)

Trimedyne reports Q3 results
Trimedyne ( OTCPK:TMED ): Q3 EPS of $0.38 More news on: Trimedyne, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 02 2018 10:06
Trimedyne Reports Its Financial Results for the Quarter Ended on June 30, 2018
Irvine, California, Aug. 02, 2018 (GLOBE NEWSWIRE) -- TRIMEDYNE, INC. (OTCPINK “TMED”) today reported its financial results for its quarter ended on June 30, 2018. For the quarter ended June 30, 2018, Trimedyne had revenues of $1,597,000, an increase of 61% from revenues of ...
Source: GlobeNewswire
Date: August, 02 2018 09:30
Trimedyne reports Q2 results
Trimedyne ( OTCPK:TMED ): Q2 EPS of $0.20 Revenue of $1.35M (+21.6% Y/Y) Press Release More news on: Trimedyne, Inc., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 03 2018 09:18
Trimedyne Reports Its Financial Results For The Quarter Ending on March 31, 2018
Irvine, CA, May 03, 2018 (GLOBE NEWSWIRE) -- TRIMEDYNE, INC. (OTCPINK “TMED”) today reported its financial results for its quarter ending on March 31, 2018. For the quarter ended March 31, 2018, Trimedyne had revenues of $1,352,000, an increase of 21% from revenues of $1,119...
Source: GlobeNewswire
Date: May, 03 2018 09:00
Trimedyne reports Q1 results
Trimedyne ( OTCPK:TMED ): Q1 EPS of $0.70 More news on: Trimedyne, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: February, 20 2018 09:23
Trimedyne Reports Its Financial Results for the Quarter Ending on December 31, 2017
IRVINE, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- TRIMEDYNE, INC. (OTCPINK:TMED) today reported its financial results for its quarter ending on December 31, 2017. For the Quarter Ended December 31, 2017, Trimedyne had revenues of $1,534,000, an increase of 40% from revenues of $1,094,000...
Source: GlobeNewswire
Date: February, 20 2018 09:00
Trimedyne reports FY results
Trimedyne ( OTCPK:TMED ): FY EPS of -$0.36 More news on: Trimedyne, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: January, 03 2018 09:05
Trimedyne Reports Its Financial Results for Its Fiscal Year Ending on September 30, 2017
IRVINE, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- TRIMEDYNE, INC. (OTCPINK “TMED”) today reported its financial results for its Fiscal Year ending on September 30, 2017. For the Fiscal Year Ended September 30, 2017, Trimedyne had revenues of $4,695,000, a decrease of 8% from...
Source: GlobeNewswire
Date: January, 03 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-11N/A8.00N/AN/A0
2018-12-10N/A8.00N/AN/A38
2018-12-078.008.008.008.00219
2018-12-068.008.008.008.001,730
2018-12-05N/A8.00N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-103838100.0000Short
2018-08-07103103100.0000Short
2018-04-09123123100.0000Short
2018-04-0611010.9901Cover
2018-03-19212680.7692Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TMED.


About Trimedyne, Inc. (OTC: TMED)

Logo for Trimedyne, Inc. (OTC: TMED)

Trimedyne, Inc. is a publicly held, ISO Certified manufacturer of lasers and disposable fiber optic delivery devices cleared for sale by the FDA for use in a variety of minimally invasive surgical applications, including, urology, lithotripsy, orthopedics, spine, arthroscopy, ENT surgery, gynecology, GI surgery, and general surgery. lt br / gt lt br / gt Trimedyne s lasers and minimally invasive, patented, single use, side firing fiber optic devices are used in urology to treat enlarged prostates, and its single use and reusable optical fibers are used to fragment urinary stones in the kidneys, ureter or bladder. Trimedyne s lasers and minimally invasive, patented, single use, side firing laser needles are also used to treat herniated or ruptured discs in the spine, typically in outpatient procedures. lt br / gt lt br / gt Trimedyne s lasers and proprietary, fiber optic laser energy delivery devices are designed to reduce the bleeding and trauma of conventional surgery, reduce or eliminate hospital stays and shorten recuperation time. Trimedyne also owns a broad portfolio of U.S. Patents covering lasers and fiber optic laser energy delivery devices. lt br / gt lt br / gt Trimedyne leases a modern , sq. ft. office and manufacturing facility in Lake Forest, California. lt br / gt lt br / gt Trimedyne s wholly owned subsidiary, Mobile Surgical Technologies, Inc. MST is a fee per case provider of lasers, laser operators, and fiber optic laser energy delivery devices to hospitals, outpatient surgery centers and physicians in Texas and adjoining states, enabling them to avoid buying a laser and hiring and training a technician to operate it. MST is based in Dallas, Texas.

 

Contact Information

 

 

Current Management

  • Marvin P. Loeb / CEO, President
  • Marvin P. Loeb / Chairman
  • Donald Baker /
  • Alan E. Loeb /

Current Share Structure

  • Market Cap: $229,574,500 - 03/09/2018
  • Issue and Outstanding: 18,365,960 - 02/20/2009

 



Daily Technical Chart for (OTC: TMED)

Daily Technical Chart for (OTC: TMED)


Stay tuned for daily updates and more on (OTC: TMED)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: TMED)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TMED is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TMED and does not buy, sell, or trade any shares of TMED. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/